XBIRA contains abiraterone acetate, which inhibits the synthesis of androgens, slowing the growth of prostate cancer cells. This drug is used in combination therapy for metastatic prostate cancer in men, particularly those who do not respond to standard treatments. It helps lower testosterone levels, slowing disease progression.
The product is used for:
Metastatic prostate cancer
Hormone-refractory prostate cancer
Used in combination with other medications to slow disease progression
XBIRA is taken orally, typically 1 tablet (250 mg) once daily, with or without food. The tablet should be swallowed whole with water. The dosage may be adjusted based on the patient's condition and treatment response.
Contraindications:
Hypersensitivity to the components of the product
Severe liver diseases
Pregnancy and breastfeeding
Hyperkalemia (elevated potassium levels in the blood)
Side Effects:
Increased blood pressure
Headache, fatigue
Nausea and vomiting
Gastrointestinal disturbances (diarrhea, constipation)
Elevated potassium levels in the blood
